Back HCV Treatment

FDA Approves Once-Daily Coformulation of AbbVie's Viekira Regimen

The U.S. Food and Drug Administration (FDA) has approved a new once-daily coformulation of AbbVie's paritaprevir-based "3D" regimen for hepatitis C virus (HCV) genotype 1, to be sold as Viekira XR, the company announced this week. AbbVie also said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on a shorter 12-week course of treatment with Viekirax for HCV genotype 4 patients with liver cirrhosis.


Read more: